Toripalimab plus chemo after surgery for small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether a combination of toripalimab (an immunotherapy drug) and chemotherapy can help prevent small cell lung cancer from coming back after surgery. It is for people who had an unexpected finding of small cell lung cancer after their tumor was removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had surgery to remove lung cancer, and the lab found that you also had small cell lung cancer (a type of fast-growing lung cancer).
- You are 18 years or older.
- You are physically active enough to be up and about (ECOG score 0 or 1).
- Your major organs (liver, kidneys, blood cells) are working well.
- You are not pregnant, breastfeeding, or planning to become pregnant during the study.
- You have no active autoimmune diseases or other cancers in the past 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding two immunotherapy drugs (toripalimab and JS004) to standard chemotherapy before surgery can help shrink limited-stage small cell lung cancer. The goal is to find better ways to treat this cancer before surgery.
This trial tests whether a combination of two immunotherapy drugs (toripalimab and JS004) plus chemotherapy can help control relapsed or extensive-stage small cell lung cancer. It is designed for people whose cancer has spread or returned and who are generally healthy enough to receive strong treatment.
This trial studies whether adding toripalimab (an immunotherapy medicine) to radiation can improve outcomes for people with operable stage II to IIIA non-small cell lung cancer. It’s designed for cancers that can be fully removed with surgery, and it aims to see if this combination helps more than radiation alone/standard care.
This trial tests a combination of an immunotherapy drug (toripalimab) and a freezing treatment (cryoablation) for people with advanced non-small cell lung cancer that has started to grow again in only a few spots after initial treatment. It aims to see if this approach can help control the cancer without switching to a completely new therapy.
This trial tests a combination of the immunotherapy drug toripalimab with standard chemotherapy for people with advanced small cell lung cancer that has gotten worse after previous treatments. It aims to see if this combination can help control the cancer.
This trial tests adding the immunotherapy drug toripalimab to chemotherapy after surgery for non-small cell lung cancer (NSCLC). It is for patients who either had no treatment before surgery or had chemo-immunotherapy before surgery and still have signs of cancer in their lymph nodes. The goal is to see if this combination helps prevent cancer from coming back.
Hear when a new Postoperative Incidental Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.